1. Home
  2. CLLS vs KNOP Comparison

CLLS vs KNOP Comparison

Compare CLLS & KNOP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CLLS
  • KNOP
  • Stock Information
  • Founded
  • CLLS 1999
  • KNOP 2013
  • Country
  • CLLS France
  • KNOP United Kingdom
  • Employees
  • CLLS N/A
  • KNOP N/A
  • Industry
  • CLLS Biotechnology: Pharmaceutical Preparations
  • KNOP Marine Transportation
  • Sector
  • CLLS Health Care
  • KNOP Consumer Discretionary
  • Exchange
  • CLLS Nasdaq
  • KNOP Nasdaq
  • Market Cap
  • CLLS 299.0M
  • KNOP 344.1M
  • IPO Year
  • CLLS 2007
  • KNOP 2013
  • Fundamental
  • Price
  • CLLS $3.85
  • KNOP $9.78
  • Analyst Decision
  • CLLS Buy
  • KNOP
  • Analyst Count
  • CLLS 1
  • KNOP 0
  • Target Price
  • CLLS $8.00
  • KNOP N/A
  • AVG Volume (30 Days)
  • CLLS 73.5K
  • KNOP 138.9K
  • Earning Date
  • CLLS 11-07-2025
  • KNOP 12-03-2025
  • Dividend Yield
  • CLLS N/A
  • KNOP 1.06%
  • EPS Growth
  • CLLS N/A
  • KNOP N/A
  • EPS
  • CLLS N/A
  • KNOP 0.69
  • Revenue
  • CLLS $82,551,000.00
  • KNOP $332,137,000.00
  • Revenue This Year
  • CLLS N/A
  • KNOP $11.88
  • Revenue Next Year
  • CLLS $58.00
  • KNOP $2.04
  • P/E Ratio
  • CLLS N/A
  • KNOP $14.15
  • Revenue Growth
  • CLLS 129.04
  • KNOP 12.14
  • 52 Week Low
  • CLLS $1.10
  • KNOP $5.28
  • 52 Week High
  • CLLS $5.48
  • KNOP $10.00
  • Technical
  • Relative Strength Index (RSI)
  • CLLS 58.54
  • KNOP 63.03
  • Support Level
  • CLLS $3.49
  • KNOP $9.76
  • Resistance Level
  • CLLS $3.86
  • KNOP $9.89
  • Average True Range (ATR)
  • CLLS 0.22
  • KNOP 0.17
  • MACD
  • CLLS 0.03
  • KNOP 0.01
  • Stochastic Oscillator
  • CLLS 89.76
  • KNOP 82.76

About CLLS Cellectis S.A.

Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.

About KNOP KNOT Offshore Partners LP Common Units representing Limited Partner Interests

KNOT Offshore Partners LP owns, operates, and shuttles tankers under long-term charters in the North Sea and Brazil. The company provides crude oil loading, transportation, and storage services under time charters and bareboat charters. The Partnership is formed for acquiring ownership interests in over four shuttle tankers owned by Knutsen NYK Offshore Tankers AS (KNOT). It operates through the shuttle tanker market segment.

Share on Social Networks: